Themis Medicare Peer Comparison

NSE: THEMISMED | BSE: 530199

₹125.48

₹-0.67 (-0.53%)

As on 28-Aug-2026IST

Market cap

₹1,160 Cr

Revenue (TTM)

₹332 Cr

P/E Ratio

P/B Ratio

Div. Yield

0.4 %

Edit

	Themis Medicare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	1,160	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	332	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	23.20	414.00	288.22	-371.81	387.35
Net Margin (%)	6.81	11.23	14.79	-3.93	26.01
RoE (%)	-5.59	8.38	29.77	-3.85	25.18
Price to Earnings	29.03	78.49	103.71	--	69.57
Price-To-Book	2.99	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Themis Medicare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	331.61	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	340.79	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	373.56	2,792.00	1,485.56	8,195.15	919.25
EBITDA	-41.94	772.00	450.24	1,010.13	542.56
Depreciation	10.31	226.00	50.83	857.51	37.68
EBIT	-52.25	546.00	399.41	152.62	504.88
Interest	11.20	217.00	40.84	342.73	3.77
Other Income	9.18	122.00	12.78	244.31	27.45
Exceptional Items	92.09	12.00	0.00	-216.88	0.00
Profit before Tax	37.82	463.00	371.35	-162.68	528.56
Provision for Tax	14.62	49.00	83.14	209.13	141.21
Profit after Tax	23.20	414.00	288.22	-371.81	387.35

	Themis Medicare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	398.58	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	33.17	1,712.00	202.03	5,044.14	42.40
Current Liabilities	166.16	1,622.00	835.87	4,758.28	230.82
Total Liabilities	597.90	8,100.00	1,451.43	15,513.53	1,549.26

	Themis Medicare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	277.82	5,343.00	519.60	10,211.52	1,026.85
Current Assets	304.98	2,606.00	1,681.81	7,191.66	881.27
Total Assets	597.90	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	82.99	1,859.00	393.17	4,720.27	8.18
Net Current Assets	138.82	984.00	845.94	2,433.38	650.46
Contingent Liabilities	25.85	770.26	12.25	99.76	15.38

	Themis Medicare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	34.71	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-12.17	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	-25.90	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	-3.36	-396.00	54.56	-25.99	155.52

	Themis Medicare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	10.37	4.07	26.97	6.61	20.14
ROE (%)	-5.59	8.38	29.77	-3.85	25.18
ROA (%)	3.91	4.94	24.77	-2.21	21.93
EBIT Margin (%)	-15.76	15.32	20.63	1.66	34.54
Net Margin (%)	6.81	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Themis Medicare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-12.76	18.37	46.65	0.78	40.90
EBIT Growth (%)	-18,170.28	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	361.15	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	-139.76	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	6.60	29.77	42.49	2.28	94.96

	Themis Medicare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	-53.32	80.56	102.12	-93.01	69.57
Price / Book Value	2.99	6.38	22.27	3.64	15.55
Dividend Yield (%)	0.40	0.00	0.08	0.00	0.08
EV/EBITDA	-29.34	43.48	66.20	32.91	49.08
Market Cap (₹ Cr)	1,349.79	23,064.69	0.00	29,731.27	19,988.69

	Themis Medicare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.05	0.31	0.11	0.53	0.01
Short term debt to equity ratio	0.11	0.11	0.54	0.12	0.02
Current Ratio	1.84	1.61	2.01	1.51	3.82
Quick Ratio	1.35	1.06	1.14	0.87	2.82
Interest Coverage	4.38	3.13	10.09	0.53	141.16

	Themis Medicare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	53.71	16.50	26.28	23.44	24.80
Asset Turnover	0.56	0.43	1.66	0.55	0.83
Receivable days	159.79	60.36	47.59	77.05	90.06
Inventory Days	69.71	64.42	62.58	77.13	61.02
Payable days	166.51	218.94	228.78	173.49	96.06
Cash Conversion Cycle	62.99	-94.15	-118.62	-19.30	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.